New drug combo shows promise for advanced lung cancer

NCT ID NCT07410611

Not yet recruiting Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Feb 14, 2026 · Last updated May 19, 2026 · Updated 12 times

Summary

This study tests a new drug (befotertinib) combined with radiation therapy for people with advanced lung cancer that has spread to a few spots (oligometastatic) and has a specific gene change (EGFR mutation). The goal is to see if this combination can delay cancer growth. About 84 adults will take part, and doctors will use a blood test (ctDNA) to monitor how well the treatment is working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE TESTED POSITIVE FOR EGFR MUTATIONS CONFIRMED BY HISTOPATHOLOGICAL EXAMINATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PATIENTS WITH ADVANCED OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE TESTED POSITIVE FOR EGFR MUTATIONS CONFIRMED BY HISTOPATHOLOGICAL EXAMINATION